Disseminated Salmonella paratyphi infection in a rheumatoid arthritis patient treated with infliximab.
Anti-tumour necrosis factor (TNF)-alpha treatments are immunosuppressant and represent an important risk factor for developing infections. We report a case of Salmonella paratyphi bacteraemia associated with soft tissue infection in a patient who used infliximab and had recently travelled to India. This case report provides supporting evidence, essentially based only on case reports, that patients receiving anti-TNF-alpha treatments have an increased susceptibility to Salmonella infections, which may develop at unusual and disseminated sites. We emphasize the importance of appropriate counselling of patients undergoing anti-TNF treatment and travelling to areas in which Salmonellae are endemic, as well as the importance of advice to these patients concerning food hygiene.
Bassetti
M
M
Infectious Diseases Division, San Martino University Hospital and University of Genoa, Genoa, Italy.
Nicco
E
E
Delfino
E
E
Viscoli
C
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000382:microbiology*; D016470:Bacteremia / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D019353:Endemic Diseases; D006801:Humans; D007194:India; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012480:Salmonella Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D012482:Salmonella paratyphi A / Q000302:isolation & purification*; D014195:Travel; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab